Cancer

November 21, 2013

Therapeutic target for synovial sarcoma

Inhibitors of a signaling pathway that is critical to synovial sarcoma tumorigenesis may be useful treatments for this aggressive cancer.

By Leigh MacMillan
November 14, 2013

Family’s support enhances cancer research training

John F. Brock III, chairman and CEO of Coca-Cola Enterprises, his wife, Mary, and their three children have established an endowment to support an oncology fellowship at Vanderbilt-Ingram Cancer Center. The Brock Family Fellowship will provide financial assistance long into the future for young physicians, postdoctoral students and medical investigators who are furthering their training in cancer research.

By VUMC News and Communications
November 13, 2013

Molecular circuits in ovarian cancer

Vanderbilt researchers have used bioinformatics analysis of gene expression data to describe molecular “circuits” that drive ovarian cancer.

By Leigh MacMillan
November 7, 2013

VU study sheds new light on DNA replication

David Cortez, Ph.D., and his Vanderbilt colleagues report new findings that shed light on fundamental processes involved in DNA replication and have implications for cancer therapies that target these processes.

By Leigh MacMillan
red laser beam
October 17, 2013

New technique tracks breast cancer subtypes, treatment effectiveness

A group of Vanderbilt researchers has used laser technology and a custom-built multiphoton microscope to distinguish breast cancer subtypes and determine if specific therapies are working against the cancer cells in as little as two days.

By VUMC News and Communications
October 10, 2013

Probing mutant EGF receptor regulation

Understanding the regulation of mutant EGF receptors commonly found in lung cancers could lead to new targeted therapies.

By Leigh MacMillan
September 26, 2013

Cell changes en route to stomach cancer

Molecular characterization of pre-cancerous changes in cells lining the stomach could point to lesions with a greater risk of progression to cancer.
By Leigh MacMillan
September 19, 2013

Hyundai award helps drive hope for cancer research

Emmanuel Volanakis, M.D., assistant professor of Pediatrics and Hematology/Oncology, was awarded a $250,000 Hyundai Hope On Wheels grant last week for his ongoing research into T-cell acute lymphoblastic leukemia (ALL), an aggressive blood cancer.
By Christina Echegaray
September 12, 2013

VU study identifies DNA changes in drug-resistant cancer cells

Vanderbilt investigators have combined next-generation sequencing technologies and bioinformatics analyses to screen for genome-wide genetic mutations associated with drug resistance in a series of lung cancer cell lines.
By Leigh MacMillan
August 26, 2013

Tumor factor spurs blood vessel growth

A newly identified factor regulates blood vessel growth in colorectal tumors and could be a promising target for cancer therapies.
By Leigh MacMillan
August 22, 2013

Overcoming resistance in ovarian cancer

The nuclear receptor TR3 contributes to ovarian cancer cell death in response to platinum-based chemotherapy – and may be a good target for overcoming cell resistance to certain treatments.
By Leigh MacMillan
August 15, 2013

$5.2M NIH grant bolsters colorectal cancer research

Robert Coffey Jr., M.D., Ingram Professor of Cancer Research at Vanderbilt University, has received a five-year, $5.2 million grant from the National Institutes of Health (NIH) to study the role of extracellular RNA (ex-RNA) in colorectal cancer.
By Bill Snyder
August 15, 2013

Komen grants bolster breast cancer research

Vanderbilt-Ingram Cancer Center investigators are receiving $1 million in breast cancer research grant funds from Susan G. Komen, the largest nonprofit foundation supporting breast cancer research.
By VUMC News and Communications
1 … 50 51 52 53 54 … 67